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Abstract
Iron accumulation has been observed in mouse models and in both sporadic and familial forms of amyotrophic
lateral sclerosis (ALS). Iron chelation could reduce iron accumulation and the related excess of oxidative stress
in the motor pathways. However, classical iron chelation would induce systemic iron depletion. We assess the
safety and efficacy of conservative iron chelation (i.e., chelation with low risk of iron depletion) in a murine
preclinical model and pilot clinical trial. In Sod1G86R mice, deferiprone increased the mean life span compared
with placebo. The safety was good, without anemia after 12 months of deferiprone in the 23 ALS patients
enrolled in the clinical trial. The decreases in the ALS Functional Rating Scale and the body mass index were
significantly smaller for the first 3 months of deferiprone treatment (30mg/kg/day) than for the first treatment-
free period. Iron levels in the cervical spinal cord, medulla oblongata, and motor cortex (according to magnetic
resonance imaging), as well as cerebrospinal fluid levels of oxidative stress and neurofilament light chains were
lower after deferiprone treatment. Our observation leads to the hypothesis that moderate iron chelation regimen
that avoids changes in systemic iron levels may constitute a novel therapeutic modality of neuroprotection for
ALS. Antioxid. Redox Signal. 29, 742–748.
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Introduction
Amyotrophic lateral sclerosis (ALS) is characterizedby rapid progressive upper and lower motor neuron de-
generation, leading to paralysis and death. Iron accumulation
has been observed in mouse models and in both sporadic and
familial forms of ALS (1, 3–6, 8, 9). Iron accumulation seems
to occur at least in microglial cells within motor cortical
regions (6) and has been observed in the motor cortex using
magnetic resonance imaging (MRI) (1, 6). In patients with
sporadic ALS, cerebrospinal fluid (CSF) levels of iron are
elevated (4) and elevated serum ferritin levels correlate with
shorter survival (9). Importantly, iron chelation has shown
therapeutically relevant protective effects in animal models
(3, 5). Deferiprone is a unique iron chelator; at low-dose
levels, it can cross membranes, decrease regional iron ac-
cumulation, redeploy the captured iron to extracellular
transferrin, and subsequently distribute iron throughout the
body (thus avoiding anemia), defining the ‘‘conservative’’
iron chelation (2).
Dose and Sex Effect on Neuroprotection
with Deferiprone in the Murine Model of ALS
A dose- and sex-dependent effect of deferiprone on
survival was observed in the SOD, superoxide dismutase
(SOD)1G86R mouse model (Fig. 1). The female mice in the
50mg/kg/day deferiprone groups survived for 13 days
longer than those in the vehicle group (Fig. 1A). This
corresponded to a 56% extension in survival from disease
onset (defined as the peak in body weight) (Fig. 1B). The
dose of 100mg/kg/day was less effective and the dose of
200mg/kg/day was not effective (not shown). A signifi-
cant effect was observed in male mice only with the highest
dose (200mg/kg/day). Deferiprone improved the animals’
physical examination, as shown by greater body weight
(Fig. 1B), a lower peak in neurological impairment (i.e., a
lower Neuroscore, a quick phenotypic neurological scoring
system) (Fig. 1C), and return of gene expression of ace-
tylcholine receptor subunit g (Chrng) to wild-type levels
(marker of denervation of muscles) (Fig. 1D). Importantly,
treated mice had less iron accumulation in the spinal cord
(shown by MRI T2* sequence) compared with vehicle con-
trol mice (Fig. 1E), demonstrating an ability of deferiprone to
hit the biological target. As with treatment in other neuro-
logical models (2), deferiprone did not induce anemia, and
serum ferritin was only marginally below normal levels at the
highest dose (Fig. 1F).
Safety Profile of Deferiprone in Early ALS Patients
Twenty-three consecutive sporadic patients were enrolled
(22 limb onset and 1 bulbar onset) (Table 1). Four patients
dropped out: one patient died after a fall, and 3 withdrew their
consent. All were compliant to medication. The non-
neurological physical examination remained unchanged. All
patients displaying normal hematologic profiles, a slight el-
evation in urine iron levels, and a transient decrease in serum
ferritin (in the normal ranges) was observed in the first 3
months of treatment.
Is There a Disease Modifying Effect of Deferiprone
in Early ALS Patients?
The decrease in the ALS Functional Rating Scale
(ALSFRS-R) score was significantly smaller for the first 3
months of deferiprone treatment than for the 3-month
treatment-free period ( p = 0.013) (Table 1). Likewise, the
decrease in the body mass index (BMI) was significantly
different, with a decrease during the first 3 months and a
small increase during the treatment period (no percutaneous
endoscopic gastrostomy feeding) ( p = 0.047). Then, the BMI
remained unchanged for 9 months. The reduction in manual
muscle testing (MMT) scores was lower in patients on de-
feriprone than in matched patients from the Mitotarget study,
although this difference did not reach statistical significance
( p= 0.09) (Table 2).
Iron Accumulation and Oxidative Stress Reduction
Under Deferiprone in Early ALS Patients
A significant decrease in iron concentration (shown by a
decrease in R2*) was observed in the cervical spinal cord, the
medulla oblongata, and the motor cortex but not in areas
outside the motor system (i.e., the cerebellum and the oc-
cipital cortex) following treatment with deferiprone. Iron
levels, oxidative stress markers, and neurofilament light
chains were lower after deferiprone treatment in the CSF
(Table 1).
Conservative Iron Chelation
The present study is a first to demonstrate the safety of
conservative iron chelation in ALS. In both a murine model of
familial ALS and sporadic ALS patients, low-dose deferiprone
was associated with a decrease in pathologic iron accumula-
tion in the central motor pathways but did not alter iron me-
tabolism in other regions of the brain or in the periphery. This
new therapeutic strategy appears to maintain the patient’s
overall aerobic metabolism and limit excess oxidative stress—
as has been observed in Parkinson’s disease (2).
Deferiprone significantly increased survival, as previously
reported with other iron chelators (3, 5). This was observed
despite treatment initiation at the symptomatic stage in the
phenotypically aggressive SOD1G86R model. An interaction
between dose and sex was observed; disease severity, iron
accumulation, and the required dose were higher in males than
in females.
Deferiprone had a good safety profile in patients, with
adverse events mostly relating to persistent ALS symptoms.
Innovation
The present work provides the first clinical evidence
about the neuroprotective potential of a therapeutically
safe chelation treatment on early-stage amyotrophic lat-
eral sclerosis (ALS) patients, which responded signifi-
cantly to treatment in both brain iron deposits and
indicators of disease progression. The novel treatment
relied on oral administration of deferiprone that by che-
lation of labile iron it conferred on oxidation-stressed
animals, improved motor functions, while essentially
sparing systemic iron. The paradigmatic modality of
chelation with deferiprone in ALS has prompted a mul-
ticenter study.
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FIG. 1. Pharmacological effects of DFP in a murine model of ALS. Data are mean–SEM in all experiments and doses,
n= 10 per group for each sex and each dose. For the females, the best dose was 50mg/kg/day, the dose of 100mg/kg/day was
less effective, and the dose of 200mg/kg/day was not inefficient. For the males, the only efficient dose was 200mg/kg/day. All
the figures are presented with the dose of 50mg/kg/day for the females and 200mg/kg/day for the males. (A) The survival rates
were significantly improved for female (in red) and male (in black) SOD1G86R mice (from disease and treatment onset onward)
in the DFP group (solid line) and the vehicle group (Veh, dotted line) (log-rank test; females: p= 0.011; males: p= 0.03). (B)
Change in body weight in female and male SOD1G86R mice from disease and treatment onset until death, in four groups: WT-
Veh (black triangles with a dotted line), WT-DFP (red triangles with a solid line), SOD1G86R-Veh (black circles with a dotted
line), and SOD1G86R-DFP (red circles with a solid line) (ANCOVA adjusted on baseline, *p< 0.05 vs. untreated SOD1G86R
mice). (C) The peak NeuroScore (a quick phenotypic neurological scoring system for evaluating disease progression in the
mouse model of ALS: 0: no impairment; 6: greatest possible impairment) in the SOD1G86R-Veh group (black bar) and the
SOD1G86R-DFP group (red bar) (Mann–Whitney test, *p< 0.05 vs. untreated SOD1G86R mice). (D) As measured by qRT-
PCR, acetylcholine receptor subunit c receptor RNA expression as a percentage (%) of the control value in the left gas-
trocnemius muscle in SOD1G86R female mice treated with 50mg/kg/day DFP (Mann–Whitney test, *p< 0.05 vs. untreated
SOD1G86R mice). (E) Magnetic resonance imaging of the cervical spinal cord at day 70 (i.e., just before the appearance of
symptoms and treatment onset) and at day 100 (i.e., with marked motor impairments before death) in untreated female
SOD1G86R mice (triangles with a black solid line), WT female mice (squares with a dotted line), and SOD1G86R female mice
treated with 50mg/kg/day DFP (red line). R2* (= 1/T2*) was obtained in a manually drawn region of interest using a
monoexponential fitting of the signal decay with the echo time (Kruskal–Wallis test *p< 0.05 vs. untreated SOD1G86R mice,
#p< 0.05 vs. WT untreated mice). (F) Serum ferritin levels (ng/mL) from serum obtained at end of treatment: not significantly
reduced after 50mg/kg/day and 100mg/kg/day (data not shown), but significantly reduced after 200mg/kg/day (Kruskal–
Wallis test *p< 0.05 vs. untreated SOD1G86R mice). ALS, amyotrophic lateral sclerosis; DFP, deferiprone; SOD, superoxide
dismutase; WT, wild type. To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars
744
T
a
b
l
e
1
.
N
e
u
r
o
l
o
g
ic
a
l
a
n
d
S
y
st
e
m
ic
P
a
r
a
m
e
t
e
r
s
in
A
m
y
o
t
r
o
ph
ic
L
a
t
e
r
a
l
S
c
l
e
r
o
si
s
P
a
t
ie
n
t
s
a
t
In
c
l
u
si
o
n
a
n
d
w
it
h
u
p
t
o
1
2
M
o
n
t
h
s
o
f
D
e
fe
r
ip
r
o
n
e
T
r
e
a
t
m
e
n
t
)
T
h
e
S
A
F
E
-F
A
IR
-A
L
S
tr
ia
l
(m
o
n
th
s)
/
B
a
se
li
n
e
V
3
3
m
o
n
th
s
o
f
n
o
tr
ea
tm
en
t
V
6
3
m
o
n
th
s
o
f
D
F
P
p
-v
a
lu
e
fo
r
V
3
v
s.
V
6
V
9
6
m
o
n
th
s
o
f
D
F
P
V
1
2
9
m
o
n
th
s
o
f
D
F
P
V
1
5
1
2
m
o
n
th
s
o
f
D
F
P
F
P
P
o
p
u
la
ti
o
n
(n
=
2
3
)
M
ea
n
–
S
D
ag
e:
5
6
.2
–
9
.8
y
ea
rs
;
4
fe
m
al
e/
1
3
m
al
e;
m
ea
n
–
S
D
d
is
ea
se
d
u
ra
ti
o
n
(s
in
ce
fi
rs
t
si
g
n
s)
:
1
1
.7
–
5
.7
m
o
n
th
s
D
ro
p
o
u
t:
4
p
at
ie
n
ts
:
1
d
ea
th
re
la
te
d
to
b
ra
in
h
em
o
rr
h
ag
e
af
te
r
a
fa
ll
an
d
3
w
it
h
d
re
w
th
ei
r
co
n
se
n
t
A
d
v
er
se
ev
en
ts
d
u
ri
n
g
V
3
–
V
1
8
(n
=
2
3
)
F
al
ls
w
it
h
o
r
w
it
h
o
u
t
tr
au
m
a
(n
=
9
);
re
sp
ir
at
o
ry
fa
il
u
re
w
it
h
o
r
w
it
h
o
u
t
b
ro
n
ch
it
is
(n
=
4
);
ar
te
ri
al
h
y
p
er
te
n
si
o
n
(n
=
2
);
tr
an
si
en
t
ch
es
t
p
ai
n
(n
=
2
);
tr
an
si
en
t
ab
d
o
m
in
al
p
ai
n
(n
=
1
);
p
u
lm
o
n
ar
y
em
b
o
li
sm
(n
=
1
);
at
ri
al
fi
b
ri
ll
at
io
n
(n
=
1
);
ar
te
ri
al
th
ro
m
b
o
si
s
(n
=
1
);
tr
an
si
en
t
n
au
se
a
(n
=
1
);
tr
an
si
en
t
p
o
st
u
ra
l
tr
em
o
r
(n
=
1
);
p
ru
ri
tu
s
(n
=
1
);
g
as
tr
it
is
(n
=
1
)
H
an
d
ic
ap
te
st
(n
=
1
9
)
A
L
S
F
R
S
-R
4
0
.5
6
4
4
1
[3
6
–
4
5
]
3
5
.6
6
7
3
6
[3
1
–
4
2
]
3
3
.1
6
8
3
3
[2
6
–
4
1
]
0
.0
1
3
*
3
1
.3
–
9
3
1
[2
6
–
4
1
]
2
9
.6
–
1
1
3
1
[2
0
–
4
0
]
2
9
–
1
1
3
5
[2
0
–
3
9
]
B
M
I
2
6
.3
6
4
2
5
[2
4
–
2
8
]
2
5
.9
6
4
2
6
[2
3
–
2
8
]
2
6
.0
6
4
2
5
[2
4
–
2
8
]
0
.0
4
7
*
*
2
6
.4
–
4
2
6
[2
4
–
2
8
]
2
6
.9
–
3
2
7
[2
4
–
2
8
]
2
5
–
3
2
4
[2
4
–
2
7
]
M
M
T
9
3
.9
–
7
9
2
[8
9
–
9
9
]
8
8
.0
–
1
1
9
0
[8
1
–
9
5
]
7
9
.4
–
1
3
7
8
[7
3
–
9
0
]
0
.3
3
*
*
7
7
.0
–
1
6
7
5
[6
8
–
8
8
]
7
5
.2
–
1
7
7
7
[6
6
–
8
4
]
7
2
–
1
4
7
2
[6
6
–
7
9
]
S
V
C
1
0
2
.6
–
1
8
1
0
2
[8
9
–
1
1
2
]
9
5
.3
–
2
0
9
0
[7
9
–
1
1
0
]
8
7
.3
–
2
5
9
0
[6
0
–
9
6
]
0
.1
*
*
7
9
.8
–
2
3
8
3
[6
7
–
9
6
]
7
8
.8
–
3
1
7
4
[5
7
–
9
6
]
7
5
–
3
5
7
6
[5
8
–
9
2
]
Ir
o
n
ac
cu
m
u
la
ti
o
n
o
n
M
R
I:
R
2
*
(s
-1
)
(n
=
1
9
)
P
re
ce
n
tr
al
-c
en
tr
al
co
rt
ex
1
4
.9
–
1
.3
1
5
.6
6
1
.4
1
4
.3
6
1
.6
0
.0
3
8
*
*
(V
3
–
V
6
)
1
3
.3
–
2
M
ed
u
ll
a
o
b
lo
n
g
at
a
1
6
.2
–
3
1
7
.4
6
2
1
5
.5
6
1
0
.0
4
7
*
*
(V
3
–
V
6
)
1
5
.7
–
2
C
er
eb
el
lu
m
1
6
.9
–
1
1
7
.1
–
1
1
6
.9
–
1
0
.3
*
*
(V
3
–
V
6
)
1
7
.1
–
1
C
er
v
ic
al
sp
in
al
co
rd
4
0
.2
6
5
.6
4
2
.2
6
5
.6
3
9
.2
6
4
.8
0
.0
0
2
*
*
(V
3
–
V
6
)
3
9
–
4
.9
F
er
ri
ti
n
an
d
ir
o
n
in
b
o
d
y
fl
u
id
s
(n
=
1
9
)
F
er
ri
ti
n
1
3
4
[1
0
0
–
1
7
5
]
1
4
3
[8
9
–
1
9
3
]
1
3
4
[7
2
–
1
7
0
]
0
.0
0
2
(V
3
–
V
6
)
1
5
0
[9
9
–
2
0
6
]
1
6
0
[1
0
1
–
2
2
0
]
F
er
ri
ti
n
(C
S
F
)
—
1
2
.3
[1
0
–
1
6
]
—
0
.0
2
7
(V
3
–
V
9
)
9
.7
[9
–
1
4
]
Ir
o
n
(u
ri
n
e)
1
1
.4
[4
–
1
9
]
1
2
.4
[8
–
1
2
]
9
8
.6
[3
2
–
9
9
]
0
.0
0
1
(V
3
–
V
6
)
8
5
[4
2
–
1
2
2
]
7
2
[2
1
–
9
9
]
O
x
id
at
iv
e
st
re
ss
m
ar
k
er
in
C
S
F
(n
=
1
9
)
8
-O
H
d
G
—
6
[5
.4
–
6
.7
]
—
0
.0
2
9
(V
3
–
V
9
)
5
.2
[5
–
6
.5
]
—
S
O
D
-1
in
C
S
F
(n
=
1
9
)
S
O
D
—
0
.6
[0
.5
–
0
.7
]
—
0
.3
(V
3
–
V
9
)
0
.6
[0
.5
–
0
.7
]
—
N
eu
ro
fi
la
m
en
ts
in
C
S
F
(n
=
1
9
)
N
fL
—
5
6
9
8
[3
3
3
2
–
9
5
9
9
]
—
0
.0
8
(V
3
–
V
9
)
3
4
9
2
[2
8
0
7
–
6
2
8
8
]
p
N
fH
—
2
5
7
8
[1
3
3
8
–
3
2
4
5
]
—
0
.3
(V
3
–
V
9
)
2
3
8
1
[1
3
6
1
–
3
2
5
5
]
—
D
at
a
ar
e
m
ea
n
–
st
an
d
ar
d
d
ev
ia
ti
o
n
(fi
rs
t
li
n
e)
an
d
m
ed
ia
n
v
al
u
e
[Q
u
ar
ti
le
1
-Q
u
ar
ti
le
3
]
(s
ec
o
n
d
li
n
e)
.
A
re
v
is
ed
A
L
S
F
R
S
-R
sc
o
re
w
as
m
ea
su
re
d
as
th
e
p
ri
m
ar
y
o
u
tc
o
m
e
in
th
e
p
at
ie
n
t
co
h
o
rt
s,
w
h
er
ea
s
B
M
I,
m
u
sc
le
st
re
n
g
th
(m
ea
su
re
d
b
y
M
M
T
),
an
d
S
V
C
w
er
e
al
so
ev
al
u
at
ed
as
se
co
n
d
ar
y
o
u
tc
o
m
es
(S
tu
d
en
t’
s
te
st
(*
)
o
r
W
il
co
x
o
n
te
st
(*
*
),
d
ep
en
d
in
g
o
n
th
e
d
is
tr
ib
u
ti
o
n
as
se
ss
ed
u
si
n
g
h
is
to
g
ra
m
s
an
d
th
e
S
h
ap
ir
o
–
W
il
k
te
st
).
Ir
o
n
co
n
te
n
t
w
as
q
u
an
ti
fi
ed
b
y
R
2
*
tr
an
sv
er
se
re
la
x
at
io
n
ra
te
s
(
=
1
/T
2
*
)
m
ea
su
re
d
u
si
n
g
a
3
-T
es
la
M
R
I
sy
st
em
(a
n
al
y
si
s
o
f
v
ar
ia
n
ce
fo
r
re
p
ea
t
m
ea
su
re
s;
th
e
st
at
is
ti
ca
ll
y
si
g
n
ifi
ca
n
t
co
n
tr
as
t
an
al
y
se
s
fo
r
V
0
vs
.
V
3
,
V
3
vs
.
V
6
,
an
d
V
6
vs
.
V
9
ar
e
in
d
ic
at
ed
).
A
d
d
it
io
n
al
se
co
n
d
ar
y
b
io
lo
g
ic
al
o
u
tc
o
m
es
w
er
e
ev
al
u
at
ed
u
si
n
g
p
re
v
io
u
sl
y
ch
ar
ac
te
ri
ze
d
as
sa
y
s.
U
n
it
s
o
b
se
rv
ed
in
co
n
tr
o
l
p
at
ie
n
ts
w
er
e
w
it
h
in
th
e
es
ta
b
li
sh
ed
ra
n
g
es
p
re
v
io
u
sl
y
re
p
o
rt
ed
.
F
er
ri
ti
n
in
C
S
F
an
d
se
ru
m
in
n
g
/m
L
.
Ir
o
n
in
u
ri
n
es
in
lg
/2
4
h
.
8
-o
x
d
G
:
D
N
A
ad
d
u
ct
o
f
8
-o
x
o
-7
,8
-d
ih
y
d
ro
-2
¢-d
eo
x
y
g
u
an
o
si
n
e
in
n
g
/m
L
(H
ig
h
ly
S
en
si
ti
v
e
8
-O
H
d
G
C
h
ec
k
,
G
en
ta
u
r
F
ra
n
ce
S
A
R
L
,
P
ar
is
,
F
ra
n
ce
),
S
O
D
in
U
/m
L
(w
h
o
le
b
lo
o
d
,
as
p
u
b
li
sh
ed
el
se
w
h
er
e8
);
N
fL
:
n
eu
ro
fi
la
m
en
t
li
g
h
t
ch
ai
n
in
p
g
/m
L
(S
im
o
a/
D
ig
it
al
E
L
IS
A
p
la
tf
o
rm
)
an
d
p
N
fH
:
p
h
o
sp
h
o
ry
la
te
d
n
eu
ro
fi
la
m
en
t
h
ea
v
y
ch
ai
n
in
p
g
/m
L
(B
io
V
en
d
o
r
k
it
)
(S
tu
d
en
t’
s
t-
te
st
(*
)
o
r
W
il
co
x
o
n
te
st
(*
*
),
d
ep
en
d
in
g
o
n
th
e
d
is
tr
ib
u
ti
o
n
as
se
ss
ed
u
si
n
g
h
is
to
g
ra
m
s
an
d
th
e
S
h
ap
ir
o
–
W
il
k
te
st
).
T
h
e
b
o
ld
v
al
u
es
ar
e
st
at
is
ti
ca
ll
y
si
g
n
ifi
ca
n
t.
A
L
S
,
am
y
o
tr
o
p
h
ic
la
te
ra
l
sc
le
ro
si
s;
A
L
S
F
R
S
-R
,
A
L
S
F
u
n
ct
io
n
al
R
at
in
g
S
ca
le
;
B
M
I,
b
o
d
y
m
as
s
in
d
ex
;
C
S
F
,
ce
re
b
ro
sp
in
al
fl
u
id
;
D
F
P
,
d
ef
er
ip
ro
n
e;
M
M
T
,
m
an
u
al
m
u
sc
le
te
st
in
g
;
M
R
I,
m
ag
n
et
ic
re
so
n
an
ce
im
ag
in
g
;
S
V
C
,
sl
o
w
v
it
al
ca
p
ac
it
y
;
S
O
D
,
su
p
er
o
x
id
e
d
is
m
u
ta
se
.
745
We did not detect any of the adverse events occasionally
observed in patients, with systemic iron overload, treated
with 100mg/kg/day deferiprone.
Encouragingly, for a safety trial with a small number of
patients, deferiprone treatment was associated with slower
disability progression and weight loss. However, the occur-
rence of a nocebo effect and then a placebo effect cannot be
ruled out, and so, a large, multicenter, double-blind, placebo-
controlled, randomized clinical trial is underway.
Materials and Methods
SOD186R transgenic mice
All animal experiments were carried out in accordance
with the ‘‘Principles of Laboratory Animal Care,’’ the current
French and European Union legislative and regulatory frame-
work (APAFIS#4269-2015112317225759), and the Euro-
pean ALS group’s preclinical trial guidelines of 2010. A
dose/response study was performed in FVB-Tg(Sod1*G86R)
M1Jwg/J mice ( JAX Laboratories) with 50, 100, or 200mg/
kg p.o. deferiprone or vehicle twice a day (10 in each group).
Study treatment was initiated at 75 days, that is, an age at
which these mice are devoid of motor symptoms but already
present with weight loss. The investigators were blinded to the
study treatment. MRI of the cervical spinal cord was done us-
ing a 7-T MR system (BioSpec Bruker, Ettlingen, Germany),
using a multiecho T2*-weighted sequence (number of echoes:
12; first echo time: 4ms; echo spacing: 7ms; repetition time:
1500ms; slice thickness: 1mm; field of view: 200· 250mm;
matrix: 256· 256; number of signal averages: 2).
Clinical trial
A single-center, single-arm, 12-month pilot clinical trial
was performed to evaluate the effect of deferiprone on pa-
tients with ALS. The patients were followed for a 3-month
treatment-free period and then treated for 12 months with the
liquid formulation of deferiprone at a dose level of 30mg/kg/
day (morning and evening dose). The patients were recruited
between December 2013 and January 2015, and all provided
written informed consent. All patients had been taking rilu-
zole. Treatment compliance (>80%) was assessed by ques-
tioning the participants and inspection of the dispensed packs
of medication. The primary outcome criterion was disease
progression, measured using the revised ALSFRS-R. The
3-month treatment-free period was compared with the first
3 months of treatment. The secondary outcomes included
MMT, BMI, slow vital capacity, and CSF levels of markers
for oxidative stress and neurofilaments. Physical exami-
nation was assessed every 3 months together with adverse
event reports and reviewed anonymously by an independent
safety monitoring board. Weekly blood counts were used to
monitor the risk of neutropenia. For exploratory purposes, 19
patients treated with deferiprone for 9 months were compared
with 19 matched individuals from among the 512 patients
in the Mitotarget trial (negative results with olesoxime;
NCT:00868166) (7).
Iron content was quantified by R2* transverse relaxation
rates (= 1/T2*) measured using a 3-Tesla MRI system
(Achieva, Philips Medical Systems, Best, The Netherlands),
using a 2D fast-field echo multiecho sequence (number of
echoes: 15; first echo time: 3.6ms; echo spacing: 3.3ms;
Table 2. Comparisons of 9 Months of Disease Progression in Patients on Deferiprone
Versus a Matched Population from the Mitotarget Trial
Parameters and populations Deferiprone treatment
Three months
of DFP treatment
Nine months
of DFP treatment pa
ALSFRS
SAFE-FAIR, mean (SD) 35.6 (6.7) 33.1 (8.2) 30.6 (11.2) 0.50
Median (IQR) 34.0 (30.0–43.0) 33.0 (26.0–41.0) (35.0) (20.0–41.0)
Mitotarget, mean (SD) 35.4 (8.4) 32.8 (9.9) 30.6 (10.5)
Median (IQR) 38.0 (30.0–42.0) 35.5 (26.5–41.0) 35.5 (23.0–38.0)
BMI
SAFE-FAIR, mean (SD) 26.0 (4.5) 26.1 (4.9) 27.4 (2.9) 0.32
Median (IQR) 25.7 (23.6–28.4) 25.5 (24.0–29.0) 27.4 (25.2–28.9)
Mitotarget, mean (SD) 23.8 (3.2) 23.2 (3.5) 23.0 (3.6)
Median (IQR) 23.2 (21.4–25.7) 21.9 (20.7–25.3) 22.5 (20.5–25.5)
MMT
SAFE-FAIR, mean (SD) 88.1 (11.8) 79.4 (13.3) 76.0 (17.9) 0.090
Median (IQR) 90.5 (80.0–96.0) 78.5 (73.0–90.0) 78.5 (68.5–85.5)
Mitotarget, mean (SD) 118.8 (26.4) 112.8 (29.7) 97.5 (39.0)
Median (IQR) 127.0 (110.0–139.0) 121.5 (86.5–135.0) 111.0 (56.0–122.0)
SVC
SAFE-FAIR, mean (SD) 96.3 (20.2) 89.4 (24.1) 82.9 (28.3) 0.97
Median (IQR) 91.6 (80.4–113.0) 90.4 (66.7–102.8) 80.7 (61.8–105.4)
Mitotarget, mean (SD) 92.1 (20.2) 84.7 (23.7) 76.4 (36.4)
Median (IQR) 92.5 (78.0–106.0) 88.0 (75.0–98.0) 75.4 (49.5–107.5)
The revised ALSFRS-R, BMI, muscle strength (measured by MMT), and SVC were evaluated.
Model for ALSFRS:
ALSFRSik¼ b0þ b1t6ikþ b2t12ikþb3Groupikþb4Groupikt6ikþ b5Groupikt12ikþ b6ALSFRSbaselinei þ c0iþ c1kþ eik. ik= for any
subject i, for any bloc k, c0iþ c1k are random effects.
The bold value is statistically significant.
ap-Value for the overall interaction between group and time, adjusted for the outcome level before DFP treatment (baseline).
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repetition time: 1803ms). Two stacks were subsequently
acquired in the axial plane; 17 slices for each (slice thickness:
2mm; isotropic, no gap, field of view: 230 · 190mm; matrix:
116 · 95; number of signal averages: 2) to cover a volume
between the floor of the fourth ventricle and the corpus cal-
losum convexity. Images were processed using a T2* tool
on an IDL virtual machine (V2, www.rsinc.com/IDL). A
monoexponential signal decay with the echo time was ob-
tained by voxel-by-voxel nonlinear least-squares fitting of the
multiecho data [S(t) = S0.e-t.R2*; where t= echo time, S =
measured signal, R2* = transverse relaxation rate]. Regions
of interest were manually drawn on R2* maps by the same
operator, who was blinded to the clinical data.
Statistical analysis
Differences in main outcomes between the treatment-free
period (months 0–3) and the first three months of deferiprone
treatment (months 3–6) were assessed with a paired T test (for
normally distributed variables) or Wilcoxon signed-rank test.
Taking into account the differences in baseline character-
istics between the patients on deferiprone and the Mitotarget
population, we performed 1:1 matching on three prespecified
factors: age (–5 years), disease duration (–2 months), and
sex. Changes in the main outcomes between month 3 and 15
(9 months of treatment) in the paired groups were compared
using linear mixed models with random coefficients. Group,
time, the group· time interaction, and the baseline value were
considered as fixed effects, with the participant and block
matching considered as random effects. All statistical tests
were two sided ( p< 0.05), and all data were analyzed using
SAS software (version 9.4, SAS Institute, Inc., Cary, NC).
Study approval
All clinical investigations were performed in accordance
with the tenets of the Declaration of Helsinki. All patients
provided written informed consent to participation. A local
institutional review board approved the aims and procedures
of the main study (national reference number: 2013-001228-
21; ClinicalTrials.gov reference: NCT02164253) and a
compassionate 12-month extension. The study and the article
followed the consort statement.
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